

A small Korean biotech just dropped MASH liver disease data that looks competitive with Novo Nordisk's blockbuster semaglutide. The catch? Only 35 patients were in the trial, and the competition is about to get fierce.
Imagine your liver is a sponge slowly hardening into a brick. That's fibrosis: healthy tissue replaced by scar tissue, inching toward cirrhosis and, eventually, liver failure. Now imagine a drug that could soften that brick back into a sponge. That's what D&D Pharmatech, a Korean biotech most people have never heard of, says its GLP-1 drug just did in a Phase 2 trial.
The company reported 48-week data for zabopegdutide (DD01), a once-weekly injectable that targets both GLP-1 and glucagon receptors. Among patients on the 40 mg dose, 50% saw their liver fibrosis improve by at least one stage without their liver inflammation getting worse. On placebo, that number was just 15.8%.
The MASH resolution numbers were even more dramatic. A full 62.5% of treated patients had their MASH resolve entirely, compared to a lonely 5.3% on placebo. That's a placebo-adjusted gap of 57.2 percentage points (p = 0.0003), which is the kind of number that makes statisticians do a double-take.
MASH (metabolic dysfunction-associated steatohepatitis) is the new name for what doctors used to call NASH. Think of it as the dangerous evolution of fatty liver disease. Your liver accumulates fat, then gets inflamed, then starts scarring. Left unchecked, it can progress to cirrhosis, liver cancer, or the need for a transplant.
Millions of Americans are affected by MASH today, and the real number is almost certainly higher because most cases go undetected. Until March 2024, there wasn't a single FDA-approved drug for it. Every major pharma company wants a piece of this massive market opportunity.
GLP-1 drugs were built for diabetes. Then they conquered obesity (hello, Ozempic and Wegovy). Now they're making a hard pivot into liver disease, and the logic is surprisingly elegant. These drugs help patients lose weight, improve insulin sensitivity, and reduce inflammation; all things that directly benefit a fatty, scarred liver.
Novo Nordisk is leading the charge. Its Phase 3 showed semaglutide (the molecule behind Wegovy) achieved MASH resolution in versus 34.1% on placebo. For fibrosis improvement, the split was 37% versus 22.5%. Those results earned a Priority Review from the FDA, with a decision expected in 2025.

The FDA just approved Decnupaz, a first-in-class antibody-drug conjugate for one of the rarest and deadliest blood cancers in existence. For the few hundred Americans diagnosed with BPDCN each year, it doubles the number of targeted therapies available overnight.


Join thousands of biotech professionals who start their day with our free, daily briefing.
So how does D&D's zabopegdutide stack up? On paper, surprisingly well. Its 57.2-percentage-point advantage in MASH resolution and 34.2-point edge in fibrosis improvement are in the same ballpark as semaglutide's numbers, possibly even better on certain measures.
But there's a catch.
D&D's trial enrolled 67 patients, with 16 patients evaluable on the treatment dose and 19 on placebo for biopsy endpoints. Semaglutide's ESSENCE trial was a full-scale Phase 3 with hundreds of participants.
Small trials are like taste-testing a single grape and declaring the whole vineyard excellent. The signal might be real, but the confidence interval is wide enough to drive a truck through. In biotech, promising Phase 2 data from tiny studies has a long and inglorious history of falling apart in larger trials.
To be fair, D&D hit statistical significance on all three of its key endpoints, including the combined measure of both fibrosis improvement and MASH resolution (37.5% vs 5.3%, p = 0.0192). The company also showed strong earlier results: at week 12, 75.8% of patients had achieved at least a 30% reduction in liver fat by MRI, compared to 11.8% on placebo.
The trajectory looks real. But "looks real in a small evaluable cohort" and "holds up in 500" are very different sentences.
Zabopegdutide isn't a plain GLP-1 agonist like semaglutide. It's a dual GLP-1/glucagon receptor agonist, which means it pulls two levers at once. The GLP-1 side handles appetite suppression, insulin secretion, and glucose control. The glucagon side directly promotes the breakdown of fat stored in the liver.
Think of it like attacking a house fire with two hoses instead of one: the GLP-1 component cuts off the fuel supply (excess calories, insulin resistance), while the glucagon component goes after the flames already burning in the liver.
D&D also has a triple agonist (DD15) in earlier development that adds GIP receptor activity on top of GLP-1 and glucagon. The company is clearly betting that more targets equal better outcomes, a hypothesis that tirzepatide's success in obesity has done a lot to validate.
D&D isn't just competing with Novo Nordisk. The MASH space is turning into one of the most crowded arenas in biopharma.
Madrigal's Rezdiffra (resmetirom) was the first FDA-approved MASH drug, working through an entirely different mechanism: activating thyroid hormone receptor-beta to directly reduce liver fat. It pulled in over $180 million in its first partial year on the market and is projected to reach $3 billion in annual sales by 2030.
Behind Rezdiffra, there's a wall of contenders. Eli Lilly's tirzepatide is being studied in MASH but won't have an FDA filing before 2027 at the earliest. Boehringer Ingelheim's survodutide, another GLP-1/glucagon dual agonist like zabopegdutide, is in Phase 3, with initial results expected around 2027–2028. FGF21 analogues from Akero (efruxifermin) and 89bio (pegozafermin) offer yet another angle of attack.
The big question for D&D: can a small Korean biotech compete in a space where Novo Nordisk, Eli Lilly, and Madrigal are already throwing billions at the problem?
D&D has FDA Fast Track designation for zabopegdutide in MASH, which helps with regulatory interactions but doesn't guarantee approval. No Phase 3 trial has been announced yet, and that's the critical next step. The company has also signed a licensing deal with Shenzhen Salubris for certain territories, suggesting it may look to partners rather than go it alone globally.
For investors and industry watchers, the takeaway is nuanced. D&D's data validates the dual agonist approach in MASH and adds to the growing mountain of evidence that GLP-1-class drugs can reverse liver scarring, not just slow it down. But the trial is too small to change clinical practice, and the competitive moat is basically nonexistent.
The MASH market is a massive opportunity that's barely been tapped. Right now, it's a land grab. D&D just planted a flag, but planting a flag and holding territory are two very different things.
The FDA's vaccine advisory committee met to pick the COVID-19 strain for 2026–2027 shots, with a new recombinant variant called XFG emerging as the leading candidate. But the bigger story might be who's still showing up to get vaccinated at all.